Browsing by Subject "Ifosfamide"
Now showing items 1-20 of 20
-
Article
-
Article
-
Article
-
Article
Combination chemotherapy with gemcitabine and vinorelbine in the treatment of relapsed or refractory diffuse large B-cell lymphoma: A phase-II trial by the Hellenic Cooperative Oncology Group
(2005)To investigate the efficacy and toxicity of the combination of gemcitabine and vinorelbine in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBL), 22 patients with relapsed or refractory DLBL were ...
-
Article
Diagnostic and therapeutic management of cancer of an unknown primary
(2003)Metastatic Cancer of Unknown Primary Site (CUP) accounts for approximately 3% of all malignant neoplasms and is therefore one of the 10 most frequent cancer diagnoses in man. Patients with CUP present with metastatic disease ...
-
Article
Effects of different chemotherapy regimens on survival for advanced cervical cancer: Systematic review and meta-analysis
(2007)Background: A large number of trials have assessed various chemotherapy regimens for the treatment of advanced cervical cancer, but there is uncertainty about the magnitude of survival benefits. Methods: We searched (last ...
-
Article
The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma
(2017)For decades, doxorubicin alone or in combination with ifosfamide has been used in advanced soft tissue sarcoma (STS). In 2014, a comparison of doxorubicin alone versus the combination with ifosfamide (in the randomised ...
-
Article
Ifosfamide plus oral etoposide salvage chemotherapy for platinum- resistant paclitaxel-pretreated ovarian cancer
(2000)Background: The prognosis of platinum resistant ovarian cancer is very poor and the treatment of choice has not been clearly defined. Patients and methods: We conducted a phase II study with the combination of ifosfamide ...
-
Article
Juvenile cancer: Improving care for adolescents and young adults within the frame of medical oncology
(2005)Despite unique tumour epidemiology, a higher cancer incidence and modest survival improvement compared to paediatric patients, adolescents and young adults aged 15-30 have not been considered as a separate, 'special' group ...
-
Article
Late toxicity in survivors from adolescent cancers
(2007)Nowadays three quarters of adolescents with cancer are cured but half of them experience a late toxic effect of antineoplastic therapy that interferes with their physical and psychosocial health. This review recapitulates ...
-
Article
Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens: Where do we stand? A literature review
(2016)Background Cervical cancer is the fourth most common cancer affecting women worldwide. Despite advances in screening and human papillomavirus (HPV) vaccination, a significant number of women present with or develop advanced ...
-
Article
Original article: Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site: A hellenic cooperative oncology group study
(1992)Summary: In this retrospective analysis 48 patients with metastatic undifferentiated carcinoma, adenocarcinoma and epidermoid carcimona of unknown origin were studied. The purpose of this analysis was to evaluate both the ...
-
Article
Prevention of chemotherapy-induced alopecia using an effective scalp cooling system
(2000)Alopecia is a distressing side-effect of cancer treatment. Taxanes (TX), anthracyclines (ANR) and etoposide (ET) have been consistently associated with significant alopecia. We studied an effective scalp cooling system, ...
-
Article
Prognostic factors in Greek patients with small cell lung cancer (SCLC). A Hellenic Cooperative Oncology Group study
(2002)Background: Prognostic factors among Greek patients with SCLC were evaluated. Patients and Methods: Data from 516 patients with SCLC treated by the Hellenic Cooperative Oncology Group were analyzed. Multivariate analysis ...
-
Article
A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16)
(1996)Background: It was recently reported that when ifosfamide was added to cisplatin and vinblastine the response rate was increased but not the survival in patients with non-small-cell lung cancer (NSCLC). The purpose of this ...
-
Article
Randomised trials comparing chemotherapy regimens for advanced non-small cell lung cancer: Biases and evolution over time
(2003)We systematically evaluated the evidence from randomised trials comparing various chemotherapy regimens for advanced non-small cell lung cancer. Across 254 eligible trials (42 661 patients), no regimens were compared in ...
-
Article
Randomized evidence on chemotherapy and hormonal therapy regimens for advanced endometrial cancer: An overview of survival data
(2006)Several chemotherapy and hormonal therapy regimens have been used in advanced endometrial cancer. In this review we have systematically evaluated the available data from randomized trials on survival. We searched MEDLINE, ...
-
Article
Survival benefits with diverse chemotherapy regimens for ovarian cancer: Meta-analysis of multiple treatments
(2006)Background: Numerous randomized trials have compared different chemotherapy regimens in women with ovarian cancer. Although ovarian cancer survival has improved in recent years, the magnitude of these incremental benefits ...
-
Article
Systemic treatment-induced gastrointestinal toxicity: Incidence, clinical presentation and management
(2012)The toxicity of cancer chemotherapy is among the most important factors limiting its use. Clear delineation and communication of benefits and risks is an essential component of treatment decisions. Gastrointestinal toxicity ...
-
Article
Weekly alternating non-cross-resistant chemotherapy for small cell lung cancer with a good prognosis: A study of the Hellenic Cooperative Oncology Group
(1999)This trial was conducted by the Hellenic Cooperative Oncology Group to improve the responses and survival in small cell lung cancer with a good prognosis, using a weekly intensive chemotherapy with alternated non-cross- ...